mGlu1 positive allosteric modulators (PAMs) reverse schizophrenia-like cortical hyperactivity and working memory deficits via SST-INs, validating mGlu1 as a therapeutic target for cognitive deficits in schizophrenia. Here, GRM1 is linked to schizophrenia.